Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex ...

On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol ...

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research ...

Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...

The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for ...

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc.

Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY) ...

Prime Medicine said it will receive a $55 million upfront payment and a $55 million investment from Bristol Myers Squibb. It will is also eligible to receive more than $3.5 billion in milestones, ...

Prime Medicine announced Monday morning that it is cutting its pipeline, and it signed a T cell therapy partnership with ...

RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- ...